CN111617107A - Pharmaceutical composition for treating colitis - Google Patents
Pharmaceutical composition for treating colitis Download PDFInfo
- Publication number
- CN111617107A CN111617107A CN202010279623.2A CN202010279623A CN111617107A CN 111617107 A CN111617107 A CN 111617107A CN 202010279623 A CN202010279623 A CN 202010279623A CN 111617107 A CN111617107 A CN 111617107A
- Authority
- CN
- China
- Prior art keywords
- tablet
- tablets
- pharmaceutical composition
- taken
- time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Abstract
The invention provides a pharmaceutical composition for treating colitis, and relates to the technical field of disease treatment. The pharmaceutical composition for treating colitis comprises the following pharmaceutical compositions: the compound endothelium corneum gigeriae galli tablet, the oryzanol tablet, the medroxyprogesterone acetate tablet, the compound diphenoxylate tablet and the prednisone acetate tablet are taken three times a day, wherein the compound endothelium corneum gigeriae galli tablet is taken 4 tablets each time, the oryzanol tablet is taken 3 tablets each time, the medroxyprogesterone acetate tablet is taken 3 tablets each time, the compound diphenoxylate tablet is taken 2 tablets each time, and the prednisone acetate tablet is taken 1 tablet each time. The pharmaceutical composition is used for treating colitis patients, so that the pain of the colitis patients is effectively relieved, the treatment effect of the colitis patients is obvious, the effect is fast, the treatment period is short, and meanwhile, the price of the medicinal composition for treatment is low, and the medicinal composition is convenient to obtain.
Description
Technical Field
The invention relates to the technical field of medicine, in particular to a pharmaceutical composition for treating colitis.
Background
Colitis is also called nonspecific ulcerative colitis, has slow onset of disease and inconsistent disease condition, and is mainly clinically manifested by diarrhea, abdominal pain, mucous stool, bloody purulent stool, tenesmus, even constipation, and inability to get stool within several days; diarrhea and constipation often occur, and are often accompanied by emaciation and hypodynamia, which are frequently recurrent attacks. Usually, the abdominal pain is dull pain or colic, and usually located in the lower left abdomen or lower abdomen. Other manifestations include loss of appetite, abdominal distension, nausea, vomiting and hepatomegaly; the left lower abdomen may have tenderness and sometimes can touch the spastic colon. The common general symptoms comprise emaciation, hypodynamia, fever, anemia and the like. In the chronic course of disease, a small number of patients suddenly worsen or develop a fulminant disease in the first time, present severe diarrhea 10-30 times a day, discharge feces containing blood, pus and mucus, and have high fever, vomiting, tachycardia, failure, water loss, electrolyte disorder, coma and even perforation of colon, and death can be caused by untimely treatment.
At present, people with colitis need to pay attention to rest, control diet and nutrition and combine common drug therapy, but the treatment effect of patients with colitis is slow, and the treatment effect is often gradually worsened in an attack period and a remission period or continuously.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides the pharmaceutical composition for treating the colitis, and solves the defects and problems in the prior art.
(II) technical scheme
In order to achieve the purpose, the invention is realized by the following technical scheme: a pharmaceutical composition for treating colitis, the pharmaceutical composition comprising: the compound endothelium corneum Gigeriae Galli tablet, oryzanol tablet, medroxyprogesterone acetate tablet, compound diphenoxylate tablet and prednisone acetate tablet, and the administration frequency of the pharmaceutical composition is three times per day.
Preferably, the compound endothelium corneum gigeriae galli tablet is taken by 4 tablets each time, and the specification of each tablet is 250 mg.
Preferably, the oryzanol tablets are taken 3 tablets each time, and the specification of each tablet is 10 mg.
Preferably, the medroxyprogesterone acetate tablets are taken 3 tablets each time, and the specification of each tablet is 2 mg.
Preferably, the compound diphenoxylate tablet is taken 2 tablets each time, and the specification of each tablet is 2.5 mg.
Preferably, the prednisone acetate tablets are taken 1 tablet at a time, and the specification of each tablet is 5 mg.
Preferably, the pharmaceutical composition further comprises an adrenal color hydrazone tablet, wherein the adrenal color hydrazone tablet is used for a patient with an ulcer symptom, the adrenal color hydrazone tablet is taken three times a day, the number of the administration tablets is 3, and the specification of each tablet is 2.5 mg.
(III) advantageous effects
The invention provides a pharmaceutical composition for treating colitis. The method has the following beneficial effects:
the pharmaceutical composition is used for treating colitis patients, so that the pain of the colitis patients is effectively relieved, the treatment effect of the colitis patients is obvious, the effect is fast, the treatment period is short, and meanwhile, the price of the medicinal composition for treatment is low, and the medicinal composition is convenient to obtain.
Detailed Description
The following will clearly and completely describe the technical solutions in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The embodiment of the invention provides a pharmaceutical composition for treating colitis, which comprises: the compound endothelium corneum Gigeriae Galli tablet, oryzanol tablet, medroxyprogesterone acetate tablet, compound diphenoxylate tablet and prednisone acetate tablet, and the administration frequency of the pharmaceutical composition is three times per day.
In the invention, the compound endothelium corneum gigeriae galli tablet is taken by 4 tablets each time, and the specification of each tablet is 250 mg; the dosage of oryzanol tablets is 3 tablets per time, and the specification of each tablet is 10 mg; the dosage of the medroxyprogesterone acetate tablets is 3 tablets per time, and the specification of each tablet is 2 mg; the compound diphenoxylate tablets are taken 2 tablets each time, and the specification of each tablet is 2.5 mg; the dosage of the prednisone acetate tablets is 1 tablet per time, and the specification of each tablet is 5 mg; the medicine composition also comprises adrenal color hydrazone tablets, and the adrenal color hydrazone tablets are used for patients with ulcer symptoms, wherein the adrenal color hydrazone tablets are taken three times a day, the number of the administration of each time is 3, and the specification of each tablet is 2.5 mg.
The first embodiment is as follows:
pei Zhongchen, male, 62 years old, peasant, Dazhuang county rain shower village people, after suffering from colitis, the chronic colitis turns into three years, the symptom is long-term diarrhea and belly, about eight times a day, evening must get up twice, accompanied by small belly swelling, pain, and feeling of falling, because nutrition absorption can not be obtained for a long time, body weakness, blood pressure is very low, the symptom of typical colitis, many big and small hospitals are visited in three years, no effect is produced, Beijing 301 hospital is visited at last twice, no effect is produced, and all hospitals tell what disease can not be detected, then go to water city hospital again, and the result is still no effect; then, the compound endothelium corneum gigeriae galli tablets, the oryzanol tablets, the medroxyprogesterone acetate tablets, the compound diphenoxylate tablets and the prednisone acetate tablets are taken for three times every day, except the adrenal color hydrazone tablets, because the patient has no ulcer symptom; in half a month, the symptoms are obviously improved, the defecation frequency is obviously reduced, after the medicine is taken for 20 to 30 days, the symptoms are completely absent, the defecation frequency is 1 to 2 times per day, the symptoms are the same as those of normal people, the disease is relatively stubborn, the required recovery period is longer, the recovery period is at least 6 months, otherwise, the disease is possibly repeated, and the patient is cured after taking the medicine for more than six months.
Example two:
the preparation method comprises the steps of Wangzhilian, female, age 67, farmers, Zaoqiang county-Cumpura people, wherein the colonitis is about 2015, the typical colonitis symptom is typical, long-term diarrhea, 8-10 times of defecation every day and tenesmus are serious, many hospitals seek medical care after the patients get ill, no good treatment effect is achieved, the compound endothelium corneum Gigeriae Galli tablet, the oryzanol tablet, the medroxyprogesterone acetate tablet, the compound diphenoxylate tablet and the prednisone acetate tablet are taken after the patients get ill for more than one year, the patients have the ulcer symptom, the adrenal color hydrazone tablets are also included in the pharmaceutical composition, all the drugs are recovered to be normal after the drugs are taken for the rest of the month, and then the drugs are completely cured in half a year in the recovery period until no relapse occurs at present.
Example three:
horse young, female, 95 years old, farmers, Dazao county people in heavy rain shower village (heart disease disappears in 11 months in 2019), colitis is about 2012, and the patients have no result after going to hospital for test and examination, and the medicines prescribed in the hospital have no effect after being eaten for a long time, and actually the patients have typical colitis symptoms, and the stool frequency is 7-8 times per day, and the patients have lower abdomen tenesmus, swelling and pain, and the patients have emaciation and hypodynamia and insomnia; the compound endothelium corneum gigeriae galli tablet, the oryzanol tablet, the medroxyprogesterone acetate tablet, the compound diphenoxylate tablet and the prednisone acetate tablet of the pharmaceutical composition are taken for three times every day, except the adrenal color hydrazone tablet, because the patient has no ulcer symptom; the symptoms are not cured in half a year, and the disease does not relapse in the course of 2019.
The pharmaceutical composition is used for treating colitis patients, so that the pain of the colitis patients is effectively relieved, the treatment effect of the colitis patients is obvious, the effect is fast, the treatment period is short, and meanwhile, the price of the medicinal composition for treatment is low, and the medicinal composition is convenient to obtain.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (7)
1. A pharmaceutical composition for treating colitis, characterized by: the method of treatment comprises administering the following pharmaceutical composition: the compound endothelium corneum Gigeriae Galli tablet, oryzanol tablet, medroxyprogesterone acetate tablet, compound diphenoxylate tablet and prednisone acetate tablet, and the administration frequency of the pharmaceutical composition is three times per day.
2. The pharmaceutical composition for the treatment of colitis according to claim 1, wherein: the compound endothelium corneum Gigeriae Galli tablet is administered in 4 tablets each time, and each tablet is 250 mg.
3. The pharmaceutical composition for the treatment of colitis according to claim 1, wherein: the number of the oryzanol tablets taken each time is 3, and the specification of each tablet is 10 mg.
4. The pharmaceutical composition for the treatment of colitis according to claim 1, wherein: the medroxyprogesterone acetate tablets are taken 3 tablets each time, and the specification of each tablet is 2 mg.
5. The pharmaceutical composition for the treatment of colitis according to claim 1, wherein: the compound diphenoxylate tablets are taken 2 tablets each time, and the specification of each tablet is 2.5 mg.
6. The pharmaceutical composition for the treatment of colitis according to claim 1, wherein: the prednisone acetate tablets are taken 1 tablet each time, and the specification of each tablet is 5 mg.
7. The pharmaceutical composition for the treatment of colitis according to claim 1, wherein: the medicine composition also comprises adrenal color hydrazone tablets, wherein the adrenal color hydrazone tablets are used for a patient with ulcer symptoms, the adrenal color hydrazone tablets are taken three times a day, the number of the administration tablets is 3, and the specification of each tablet is 2.5 mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010279623.2A CN111617107A (en) | 2020-04-10 | 2020-04-10 | Pharmaceutical composition for treating colitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010279623.2A CN111617107A (en) | 2020-04-10 | 2020-04-10 | Pharmaceutical composition for treating colitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111617107A true CN111617107A (en) | 2020-09-04 |
Family
ID=72267041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010279623.2A Pending CN111617107A (en) | 2020-04-10 | 2020-04-10 | Pharmaceutical composition for treating colitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111617107A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040038954A1 (en) * | 1999-09-28 | 2004-02-26 | University Of Pennsylvania | Method of treating inflammatory conditions with progesterone or progesterone analogs |
| CN101057852A (en) * | 2007-04-28 | 2007-10-24 | 王留柱 | Compound enteritis capsule |
| CN101366932A (en) * | 2008-10-10 | 2009-02-18 | 张波 | Traditional Chinese medicine preparation for treating ulcerative colitis |
| CN109069619A (en) * | 2015-12-17 | 2018-12-21 | 葛兰素史密丝克莱恩生物有限公司 | Adjuvant is used to prevent and/or treat the purposes of autoimmunity disease |
-
2020
- 2020-04-10 CN CN202010279623.2A patent/CN111617107A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040038954A1 (en) * | 1999-09-28 | 2004-02-26 | University Of Pennsylvania | Method of treating inflammatory conditions with progesterone or progesterone analogs |
| CN101057852A (en) * | 2007-04-28 | 2007-10-24 | 王留柱 | Compound enteritis capsule |
| CN101366932A (en) * | 2008-10-10 | 2009-02-18 | 张波 | Traditional Chinese medicine preparation for treating ulcerative colitis |
| CN109069619A (en) * | 2015-12-17 | 2018-12-21 | 葛兰素史密丝克莱恩生物有限公司 | Adjuvant is used to prevent and/or treat the purposes of autoimmunity disease |
Non-Patent Citations (5)
| Title |
|---|
| J. ENGBAEK ET AL.: "The constipating effect of diphenoxylate (Retardinr) in ulcerative colitis. A double-blind controlled trial", 《SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY》 * |
| 徐守仁: "《中国医学论文汇集》", 30 June 2004, 中医古籍出版社 * |
| 徐峰: "《常见病的非常规药物治疗：超说明书用药》", 31 January 2012, 中国医药科技出版社 * |
| 陈企望等: "《临床常用中药手册》", 31 October 1994, 中国医药科技出版社 * |
| 韩其邦等: "《健康长寿要旨》", 30 November 1993, 中国中医药出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103429236B (en) | Treatment hyperuricemia and the method and composition of the metabolic disorder relevant to hyperuricemia | |
| Shubin et al. | Bacterial shock: A serious complication in urological practice | |
| Long et al. | Clinical observation on the treatment of chronic urticaria with total glucosides of paeony capsule combined with citirizine | |
| CN113274384A (en) | Application of oryzaol in preparation of medicine for preventing and treating ulcerative colitis and medicine thereof | |
| CN108272802A (en) | A kind of combination medicine for treating ulcerative colitis | |
| CN111617107A (en) | Pharmaceutical composition for treating colitis | |
| KR20210048801A (en) | Composition for preventing or treating inflammatory bowel disease comprising sulglycotide as effective component | |
| CN102198089A (en) | Application of lauromacrogol injection as medicament for treating internal hemorrhoid | |
| Brodkin | Myoglobinuria following epsilon-aminocaproic acid (EACA) therapy: case report | |
| Carr Jr et al. | Death due to hepatic necrosis in a patient receiving zoxazolamine: Report of a case and review of the literature | |
| JP7157253B2 (en) | Chinese herbal composition for enema constipation, its preparation method and its use | |
| Valtonen | A comparative short-term trial with Voltaren (diclofenac sodium) and naproxen in soft-tissue rheumatism | |
| CN113350425A (en) | Traditional Chinese medicine composition for rapidly relieving inflammatory activity of ulcerative colitis and application thereof | |
| Hanazaki et al. | Effect of Daikenchuto (TJ-100) on abdominal bloating in hepatectomized patients | |
| Connell et al. | Treatment of chronic non-specific diarrhoea | |
| Liu et al. | Efficacy of the Panax notoginseng Ejiao suppository in the treatment of patients with ulcerative proctitis and its effect on inflammatory response and immune function | |
| CN115414369B (en) | Application of cucurbitacin C in preparation of medicines for preventing or treating inflammatory bowel disease | |
| Dubois | Paramethasone in the Treatment of Systemic Lupus Erythematosus: Analysis of Results in 51 Patients with Emphasis on Single Daily Oral Doses | |
| AL‐Waili | Prostaglandin synthetase inhibition with indomethacin rectal suppositories in the treatment of acute and chronic urinary calculus obstruction | |
| Chen et al. | Amitriptyline plus hydrodistension versus hydrodistension alone for treating interstitial cystitis/bladder pain syndrome | |
| CN114272254B (en) | Application of combination of glycyrrhetinic acid and paeoniflorin in treating liver injury and liver fibrosis | |
| Watanabe et al. | Intravesical indwelling lidocaine‑releasing devices for IC/BPS | |
| KR20190001682A (en) | Chinese medicine for treating children constipation | |
| CN105920035A (en) | Oral particles for acute pancreatitis prognostic nursing | |
| RU2039566C1 (en) | Method for treating inflammatory and dystrophic diseases of mucous membranes of digestive organs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200904 |